A new publication on difelikefalin appeared on September 1, 2026, in the Journal of the American Academy of Dermatology. The paper, titled "JAAD Game Changer: A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus," reports on a phase 2 study. The study examined an oral formulation of difelikefalin in subjects with chronic kidney disease who experience moderate-to-severe pruritus. Difelikefalin is currently an approved compound. This entry reflects only the fact of publication in JAAD on the stated date. No findings, outcomes, or efficacy data from the study are included here. Readers interested in the specific results should consult the original publication directly through the listed source. For broader context on difelikefalin, including its approved uses and background, readers can refer to the compound overview.
Phase 2 Oral Difelikefalin Study in CKD Pruritus Published in JAAD
See the full difelikefalin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42297298/